Results 341 to 350 of about 47,434 (363)
Some of the next articles are maybe not open access.
Enrichment and Analysis of ctDNA
2019ctDNA provided by liquid biopsy offers a promising alternative to tumor biopsy as it gives a non-invasive and «real-time» access to the cancer genome and reflects tumor intra and extra heterogeneity. ctDNA has shown growing clinical interest for cancer diagnosis, prognosis, theragnostics, therapeutic monitoring, and clonal evolution tracking.
openaire +4 more sources
ctDNA: Moving toward Clinical Utility
Cancer Discovery, 2022Abstract Findings from the phase II DYNAMIC study suggest that circulating tumor DNA analyses could help clinicians decide whether patients with stage II colon cancer require chemotherapy after standard surgery. Liquid biopsies could also shed light on the development of resistance to KRASG12C inhibition, paving the way for better ...
openaire +2 more sources
Journal of Clinical Oncology
LBA507 Background: In monarchE (NCT03155997), 2 years of adjuvant abemaciclib + ET resulted in sustained improvement in invasive disease-free survival (IDFS; HR=0.680, 7.6% absolute benefit at 5 years) in patients (pts) with HR+, HER2-, node-positive ...
S. Loi +14 more
semanticscholar +1 more source
LBA507 Background: In monarchE (NCT03155997), 2 years of adjuvant abemaciclib + ET resulted in sustained improvement in invasive disease-free survival (IDFS; HR=0.680, 7.6% absolute benefit at 5 years) in patients (pts) with HR+, HER2-, node-positive ...
S. Loi +14 more
semanticscholar +1 more source
Review ctDNA and Breast Cancer
2019In only few years, circulating tumor DNA (ctDNA) in breast cancer has moved from purely fundamental research to nearby daily use for treatment selection and drug-resistance assessment. Indeed, technical advances and widespread use of next-generation sequencing or digital PCR allowed for detection of very low amount of tumor DNA in bloodstream.
openaire +4 more sources
Dynamic Treatment Stratification Using ctDNA
2019An accurate profiling of the genomic landscape is mandatory to establish the best clinical and therapeutic approach for patients with solid malignancies. Moreover, tumor cells constantly adapt to external pressures-i.e., systemic treatment-with the selection and expansion of resistant subclones and the emergence of heterogeneous overlapping genomic ...
Joana Vidal +2 more
openaire +3 more sources
Adjuvant Immunotherapy Best for ctDNA+ Bladder Cancer
Cancer Discovery, 2021Abstract A liquid biopsy may help identify patients with operable urothelial cancer who stand to benefit from adjuvant immunotherapy. In the IMvigor010 study, patients who tested positive for circulating tumor DNA showed improvement in disease-free survival and overall survival if they received adjuvant atezolizumab instead of ...
openaire +2 more sources
ctDNA in the reading room: A guide for radiologists
European Journal of RadiologyLiquid biopsy with sequencing of circulating tumor DNA (ctDNA) is a minimally invasive method for sampling body fluids and offers a promising alternative to tissue biopsies that involve greater risks, costs, and time. ctDNA not only identifies actionable targets by revealing unique molecular signatures in cancer, but also may assess treatment response,
Hayes, Pearce +7 more
openaire +2 more sources
Practical recommendations for using ctDNA in clinical decision making
Nature, 2023S. Cohen, Minetta C. Liu, A. Aleshin
semanticscholar +1 more source
Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer
Nature, 2022C. Herberts +21 more
semanticscholar +1 more source